56
Views
43
CrossRef citations to date
0
Altmetric
Drug Evaluation

Gemcitabine in transitional cell carcinoma of the urothelium

Pages 11-19 | Published online: 10 Jan 2014

References

  • Plunkett W, Huang P, Searcy CE et al.
  • •Gemcitabine: preclinical pharmacology and mechanisms of action. Semtn. Oncol. 23(Suppl. 10), 3–15 (1996).
  • Storniolo AM, Allerheiligen SRB, Pearce
  • •HL. Preclinical, pharmacologic and Phase I studies of gemcitabine. Sonia Oncol 24\(Supp1.7), 2–7 (1997).
  • Gandhi V, Plunkett W, Du M et al.
  • ••Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a Phase I trial in relapsed acute myelogenous leukemia. J. Gun. Oncol 20, 665–673 (2002).
  • Roth BJ. Chemotherapy for advanced bladder cancer. Semin. Oncol 23, 633–644, (1996).
  • Harker WG, Meyers FJ, Freiha FS et al Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regime for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J. Gin. Oncol 3, 1463–1470 (1985).
  • Sternberg CN, Yagoda A, Scher HI et al Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. j Urol 133, 403–407 (1985).
  • Sternberg CN, Yagoda A, Scher HI et al.
  • •Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer64, 2448–2458 (1989).
  • Mead GM, Russell M, Clark P et al A
  • •randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br. Cancer 78,1067-1075 (1998).
  • Bajorin DF, Dodd PM, Mazumdar M
  • ••et al Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.j Gin. Oncol 17, 3173–3181 (1999).
  • Dodd PM, McCaffrey JA, Herr H et al.
  • •Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J. Gun. Oncol 17, 2546–2552, (1999).
  • Tannock I, Gospodarowicz M, Connolly J, Jewett M. MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. Unol. 142, 289–292 (1989).
  • Connor JP, Olsson CA, Benson MC et al Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern. Urology34, 353–356 (1989).
  • Igawa M, Ohkuchi T, Ueki T et al. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. Unol. 144, 662–665 (1990).
  • Boutan-Laroze A, Mahjoubi M, Droz JP et al MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. Eur. I Cancer27, 1690–1694 (1991).
  • Loehrer PJ Sr, Einhom LH, Elson PJ et al
  • •A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a co operative group study. J. Gin. awl. 10, 1066–1073 (1992).
  • Logothetis CJ, Dezeus FH, Finn L et al
  • •A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Gun. Oncol 8, 1050–1055 (1990).
  • Saxman SB, Propert KJ, Einhorn LH et al
  • •Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a co-operative group study.j Gin. awl. 15, 2564–2569 (1997).
  • Seidman AD, Scher HI, Gabrilove JL et al Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial carcinoma. J. Gun. Oncolll, 408–414 (1993).
  • Loehrer PJ Sr, Elson P, Dreicer R et al Escalated dosages of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma. An Eastern Co-operative Oncology Group trial. j Gun. Oncol 12, 483–488 (1994).
  • Logothetis CJ, Finn LD, Smith T et al Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J. Clin. aka 13, 2272–2277 (1995).
  • Sternberg CN, de Mulder PH,
  • •Schornagel J et al Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no 30924. J. Clin. arca 19, 2638–2646 (2001).
  • von der Maase H. Current and future
  • ••perspectives in advanced bladder cancer: Is there a new standard? Semin. Oncol 29(Suppl. 3), 3–14 (2002).
  • Pollera CF, Ceribelli A, Crecco M, Calabresi E Weekly gemcitabine in advanced bladder cancer: a preliminary report from a Phase I study. Ann. Oncol 5, 182–184 (1994).
  • Lorusso V, Pollera CF, Antimi M et al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. Cancer 34, 1208–1212 (1998).
  • Stadler WM, Kuzel T, Roth B et al. Phase II
  • •study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. Clin. aka 15, 3394–3398 (1996).
  • Moore MJ, Tannock IF, Ernst DS et al.
  • •Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. 1 Clin. arca 15, 3441–3445 (1997).
  • Gebbia V, Testa A, Borsellino N et al. Single agent 2', 2 --difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a Phase II study. Clin. Tr 150, 11–15 (1999).
  • Albers P, Siener R, Hartlein M et al Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma — prognostic factors for response and improvement of quality of life. Onkologie 25, 47–52 (2002).
  • Marenco D, Castagneto B, zai s et al. Gemcitabine monochemotherapy in the elderly patient with advanced bladder cancer. Proc. Am. Soc. Clin. Oncol 21, 150b (2002) (Abstract 2414).
  • Peters GJ, Bergman AM Ruiz, van
  • •Haperen VW et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. arca 22, 72–79 (1995).
  • von der Maase H, Andersen L, Crinó L
  • •et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothielum: a Phase II clinical trial. Ann. Oncol 10, 1461–1465 (1999).
  • Kaufman D, Raghavan D, Carducci M
  • •et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 18, 1921 1927 (2000).
  • Moore JM, Winquist EIN, Murray N et al.
  • •Gemcitabine plus cisplatin, an active regime in advanced urothelial cancer: a Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol 17, 2876–2881 (1999).
  • Lorusso V, Manzione L, De Vita F et al.
  • •Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a Phase II multicenter trial. J. Um]. 164, 53–56 (2000).
  • Wilson JJ, Winquist E, Dorreen M et al. A Phase II trial of gemcitabine plus day 1 cisplatin given on a 21 day schedule in patients with advanced unresectable or metastatic bladder cancer. Proc. Am. Soc. Clin. Oncol 21, 151b (2002) (Abstract 2418).
  • von der Maase H, Hansen SW Roberts JT
  • ••et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. Clin. Oncol 18, 3068–3077 (2000).
  • Stadler WM, Hayden A, von der Maase H
  • •et al. Long-term survival in Phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Um]. Oncol 7, 153 157 (2002).
  • Fossa SD, Sternberg C, Scher HI et al. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br. J. Cancer7 4, 1655–1659 (1996).
  • Sengelov L, Kamby C, Geertsen P et al.
  • ••Predictive factors of response to cisplatin based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Phannacol 46, 357–364 (2000).
  • Sengelov L, Kamby C, von der Maase H.
  • ••Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. FIR: Um]. 39, 634–642 (2001).
  • Sternberg CN, Calabró F, Pizzocaro G
  • •et al. Chemotherapy with an every-2-week regime of gemcitabine and paditaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92, 2993–2998 (2001).
  • Kaufman DS, Carducci MA, Kuzel T et al. Gemcitabine (G) and paditaxel (P) every two weeks (GP2W): a completed multicenter Phase II trial in locally advanced or metastatic urothelial cancer (Uc). Proc. Am. Soc. Clin. Oncol 21, 192a (2002) (Abstract 767).
  • Meluch AA, Greco FA, Burris HA III
  • •et al Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma of the urothelial tract: a Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. arca 19, 3018–3024 (2001).
  • Pectasides D, Aravantinos G, Kalofonos H et al. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A Phase II trial conducted by the Hellenic Co-operative Oncology Group. Ann. aka 12, 1417–1422 (2001).
  • Nogué M, Caries J, Arrivi A et al. Palliative chemotherapy with gemcitabine (Gem) and carboplatin (CBDCA) in advanced transitional cell carcinoma of the urothellum (ATCCU). Preliminary results. Proc. Am. Soc. Clin. aka 19, 345a (2000) (Abstract 1359).
  • Caries J, Nogué M, Domenech M et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology59, 24–27 (2000).
  • Hussain M, Vaishampayan U, Du W et al.
  • ••Combination paditaxel, carboplatin and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. aka 19, 2527–2533 (2001).
  • Bellmunt J, Gulllem V, Paz-Ares L et al.
  • ••Phase I—II study of paditaxel, cisplatin and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J. Gin. amyl 18, 3247–3255 (2000)
  • Bellmunt J, Albanell J, Paz-Ares L et al.
  • ••Pretreatment prognostic factors for survivial in patients with advanced urothelial tumors treated in a Phase I/II trial with paditaxel, cisplatin gemcitabine Cancer 95, 751–757 (2002)
  • Pectasides D, Glotsos J, Bountouroglou
  • •N et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transtitonal cell urothelial cancer: a Phase II trial. Ann. Oncol. 13, 243–250 (2002).
  • Pagliaro LC, Millikan RE, Tu SM et al. Cisplatin, gemcitabine and ifosfamide transitional-cell carcinoma. J. Gin. 20,2965–2970 (2002).
  • Droz J-P, Fizazi K, Beuzeboc P et al. Gemcitabine and cisplatin (GC) as adjuvant chemotherapy for locally advanced bladder cancer (LABC) after cystectomy: preliminary results of a feasibility study. Proc. Am. Scc. Gin. 153b (2002) (Abstract 2425). Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Sernin. Oncol 24\(Suppl. 7), 24–28 (1997). Fields MT, Eisbruch A, Normolle D et al. Radiosensitization produced in vivo by once- vs. twice weekly 2'2 --difluoro-2 deoxycytidine (gemcitabine). hit. J. Rad. Oncol Biol. Phys. 47,785-791 (2000). Robinson BVV, Shewach DS. Radiosensitization by gemcitabine in p53 wild type and mutant MCF-7 breast carcinoma cell lines. Clin. Cancer Res.7, 2581–2589 (2001). Lawrence TS, Davis MA, Hough A et al. The role of apoptosis in 2',2--difluoro-2-deoxycytidine (gemcitabine) -mediated radiosensitization. Clin. Cancer Res. 7, 314 319 (2001).
  • Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin. Oncol. 24\(Suppl. 7), 24–28 (1997).
  • Fields MT, Eisbruch A, Normolle D et al. Radiosensitization produced in vivo by once- vs. twice weekly 2'2' diffuoro2' dexoycytidine (gemcitabine). Int J. Rad. Oncol. Biol. Phys. 47, 785–791 (2000).
  • Egorin MJ, Zuhowski EG, Laufer M et al. Plasma pharmacokinetics and urinary recovery of intravesically administered gemcitabine. Proc. Am Soc. Gin Oncol 90a (2002) (Abstract 359).
  • Dalbagni G, Russo P, Sheinfeld J et al.
  • •Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J. Gin. awl. 20,3193-3198 (2002).
  • Crawford ED. Intravesical therapy for
  • •superficial cancer: need for more options. J. Gin. awl. 20,3185-3186 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.